The oncology test market in India is set to expand at a compound annual growth rate (CAGR) of approximately 2% through 2033, as reported by GlobalData. This growth reflects the rising burden of cancer and the growing demand for advanced diagnostic and treatment solutions. Contributing factors include lifestyle changes, environmental challenges, and an aging population, all of which intensify the need for effective cancer care.
India accounted for over 3% of the Asia-Pacific (APAC) oncology test market in 2024, with aspirations to address both domestic and global healthcare needs by fostering innovation and advanced research.
Strand Life Sciences: A Leap Toward Early Detection
Bengaluru-based Strand Life Sciences, a Reliance Industries Ltd. subsidiary, recently launched CancerSpot, an innovative blood-based test designed for the early detection of multiple cancers. Utilizing advanced methylation profiling technology, the test identifies tumor DNA fragments in the bloodstream. This globally recognized technology is calibrated for Indian cohorts, ensuring adaptability across diverse populations.
“Tailored diagnostics, such as genomic tests, enhance early detection accuracy, improve risk assessment, and ensure treatments align with the unique genetic profiles of Indian patients,” stated Shreya Jain, Medical Devices Analyst at GlobalData. She highlighted that such advancements not only improve survival rates locally but also contribute to global cancer research.
Challenges and Opportunities in India’s Oncology Landscape
Despite promising advancements, India’s oncology sector faces hurdles such as limited access, affordability concerns, and slow adoption of cutting-edge technologies like AI-assisted diagnostics and precision medicine. Strand Life Sciences’ Genomics Diagnostics & Research Centre aims to address these challenges by driving research and innovation in oncology, paving the way for accessible and minimally invasive cancer diagnostic solutions.
With the integration of solutions like CancerSpot, the oncology test market in India is poised to evolve, offering hope for proactive cancer management and bridging gaps in healthcare accessibility.
